If you’re on Medicare, there’s some genuinely good news coming your way. The federal government is taking major steps to permanently lower what you pay for prescription drugs. A new proposed rule from the Centers for Medicare & Medicaid Services (CMS) builds on an already successful drug price negotiation program, and it could mean real savings at the pharmacy counter. Here’s what you need to know and why it matters for your health and your wallet.
What Is the Negotiation Program?
You may have heard that Medicare hasn’t always been allowed to negotiate drug prices directly with pharmaceutical companies. That changed with the Inflation Reduction Act, which gave Medicare the legal authority to negotiate prices on some of the most expensive and widely used drugs. The program has already been up and running for a couple of years, and it’s producing results that directly benefit you.
So far, CMS has negotiated lower prices on 25 high-cost, single-source drugs. These are brand-name medications with no generic equivalent, which tend to be among the priciest drugs seniors rely on. Starting January 1, 2026, the negotiated prices on the first 10 of those drugs went into effect, which means many Medicare beneficiaries are already paying less at the pharmacy than they were before.
How the New Rule Makes It Permanent
Up until now, the Negotiation Program has been run through agency guidance, meaning the rules could change from year to year. The new proposed rule would change that by locking the program into permanent federal regulations. For you, that means the savings and the process behind them aren’t going anywhere. It creates a stable, predictable system that you, your doctor, and your pharmacist can all count on.
The rule also outlines how future rounds of negotiation will work. CMS plans to select up to 20 additional drugs for each new cycle of negotiations, starting with drugs that will have negotiated prices in effect for 2029. Over time, that means more medications could be covered under negotiated pricing, which expands your potential savings. The program isn’t just a short-term fix; it’s being built to last.
The proposed rule also includes a narrow but important update to how CMS identifies which drugs qualify for negotiation. Specifically, it addresses situations where drug manufacturers create new formulations of an existing medication in ways that could sidestep the program. By closing that potential loophole, CMS is making sure the program stays focused on delivering genuine savings rather than allowing workarounds that could undermine the whole effort. That kind of program integrity protection matters for you, because it keeps the focus where it belongs.
What This Means at the Pharmacy Counter
One of the most important things you need to understand is how these negotiated prices reach you. The rule would require Medicare Part D prescription drug plans to include the negotiated drugs on their formularies, which are the official lists of covered medications. That means your plan can’t simply leave these drugs off the list to avoid paying the negotiated price.
The rule also sets clear limits on what pharmacies can charge. Under the proposed changes, the price you’re charged for a selected drug can’t exceed the Maximum Fair Price (MFP) plus a dispensing fee. In plain language, that means the savings CMS negotiates with drug manufacturers are actually passed through to you, rather than getting lost somewhere in the system. What’s negotiated on your behalf is what you should actually pay.
Protections for Small Biotech Drugs
Price negotiation sounds great, but you may wonder if it has any downsides. For example, could it slow down the development of new medications, especially for serious conditions like cancer or rare diseases? That’s a fair concern, and the proposed rule does address it. CMS is required by law to implement what’s called a Temporary Floor for Small Biotech Drugs, and this rule would put that protection into action.
Essentially, this means CMS won’t be able to negotiate prices for certain small biotech drugs below a set minimum during 2029 and 2030. Small biotech companies typically don’t have the same financial resources as large pharmaceutical corporations, so this floor is meant to make sure that smaller, innovative drug makers aren’t priced out of the market. The goal is to keep new treatments coming while still making existing drugs more affordable for you. It’s a balance between saving money today and encouraging the medical breakthroughs you might need tomorrow.
What You Should Do Right Now
Even though the new rule is still in the proposal stage, the savings from the first round of negotiations are already real and already in effect. If you’re taking one of the 10 drugs with a negotiated price that went into effect in January 2026, you may already be paying less without realizing it. It’s worth calling your pharmacy or checking with your Medicare Part D plan to confirm you’re getting the negotiated price.
If you’re not currently enrolled in Medicare Part D, or if you’re wondering whether your current plan covers the drugs you take, now is a good time to review your options. Make sure your medications are on your plan’s formulary and that you’re enrolled in a plan that takes full advantage of available savings. Don’t wait until open enrollment season to ask questions. Medicare rules and plan options can change, and staying on top of them throughout the year puts you in a much stronger position when it’s time to make decisions.
It’s also worth knowing that you can access selected drugs at local, independent, and long-term care pharmacies across the country, not just at major chains. So if you prefer to stay with your neighborhood pharmacy, you don’t have to switch. The program was designed with access in mind, and CMS has built the infrastructure to make sure the negotiated prices flow through to you no matter where you fill your prescriptions.
Conclusion
The Medicare Drug Price Negotiation Program represents one of the most significant changes in prescription drug coverage for seniors in decades. It’s not just a policy win on paper. It’s already translating into lower costs for beneficiaries. And with this proposed rule, the program is being set up to grow, stabilize, and deliver even greater savings in the years ahead.
As this rule moves through the federal rulemaking process, it’s a good time to make sure you understand how your Medicare drug coverage works. It’s equally important to know whether you’re making the most of what benefits are available to you. For more information about Medicare, please call 866-633-4427 to speak with a Senior Healthcare Solutions Medicare expert.
